<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03220386</url>
  </required_header>
  <id_info>
    <org_study_id>EA1/055/17</org_study_id>
    <nct_id>NCT03220386</nct_id>
  </id_info>
  <brief_title>Methicillin-sensitive and Methicillin-resistant Staphylococcus Aureus (MSSA/MRSA) - Point-of-care-testing (POCT) in Clinical Decision Making</brief_title>
  <acronym>EPICS-6</acronym>
  <official_title>Methicillin-sensitive and Methicillin-resistant Staphylococcus Aureus (MSSA/MRSA) - Point-of-care-testing (POCT) in Clinical Decision Making</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study EPICS-6 consists of three study phases. Emergency Department patients are screened
      for nasal and pharyngeal colonisation with Methicillin sensitive and Methicillin resistant
      Staphylococcus aureus (MSSA/MRSA) using a point-of-care (POC)-PCR-testing method
      (cobas®LIAT®-System, Roche Molecular Systems Inc.) The first aim of this study is to describe
      the prevalence of MSSA/MRSA-colonisation in a routine cohort of Emergency Department
      patients. The second aim is to determine the impact of POC-guided decolonisation as compared
      to conventional laboratory testing on in-hospital infection rates with MSSA/MRSA in a
      pre-post-comparison study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study EPICS-6 consists of three study phases. In phase one the novel POC-PCR-testing
      method for MSSA/MRSA-proof (cobas®LIAT®-System, Roche Molecular Systems Inc.) is technically
      established and integrated in Emergency Department procedures. After evaluation of processes
      and sample handling the second phase of this study assesses the prevalence of positive
      MSSA/MRSA-POC-testing in the general ED-population and in different risk groups. Based on the
      results of the previous study phases, the final phase comprises an interventional
      pre-post-comparison study. The interventional study assesses the impact of POC-result guided
      early decolonisation of MSSA/MRSA-colonized patients on in-hospital infection rates with
      MSSA/MRSA.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">August 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients screened positive for nasal MSSA or MRSA colonization during their treatment in the emergency department receive a standardized decolonization Treatment (Octinidin nasal ointment and skin washing)</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MSSA/MRSA prevalence in a general ED-population</measure>
    <time_frame>on admission to the ED</time_frame>
    <description>number of patients with a positive POC-test result for nasal/oral MSSA/MRSA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MSSA/MRSA in-hospital infection rates</measure>
    <time_frame>at discharge from hospital for up to 90 days after admission</time_frame>
    <description>number of in-hospital MSSA/MRSA infections in patients with known nasal/oral colonization with MSSA/MRSA. This outcome measure will be assessed for the time period between admission and discharge from hospital for up to 90 days after study inclusion. It will be assessed by routine MSSA/MRSA in-hospital testing and the respective test results will be retrieved from the hospital Information system.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Staphylococcus Aureus</condition>
  <arm_group>
    <arm_group_label>Emergency Department patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients will be tested for nasal MSSA/MRSA-colonization. Patients tested positive for nasal MSSA/MRSA-colonization receive a decolonization treatment. This treatment includes octinidin nasal treatment and skin washings.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Decolonization by nasal Octinidin treatment and skin washings</intervention_name>
    <description>Patients receive nasal Octinidin treatment and skin washings for five consecutive days</description>
    <arm_group_label>Emergency Department patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 18 years

          -  Emergency Department (ED) visit in one of the participating EDs

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Martin Möckel, PhD, MD</last_name>
    <phone>+49 30 450 553 472</phone>
    <email>martin.moeckel@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Slagman, VMD, MSc</last_name>
    <phone>+49 30 450 665 659</phone>
    <email>anna.slagman@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité Universitätsmedizin - Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Möckel, Prof. Dr.</last_name>
      <phone>0049 30 553472</phone>
      <email>martin.moeckel@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Anna Slagman, Dr. MSc.</last_name>
      <phone>004930450553037</phone>
      <email>anna.slagman@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Dorothee Riedlinger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2017</study_first_submitted>
  <study_first_submitted_qc>July 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2017</study_first_posted>
  <last_update_submitted>July 17, 2017</last_update_submitted>
  <last_update_submitted_qc>July 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Martin Moeckel</investigator_full_name>
    <investigator_title>Professor Dr. med.</investigator_title>
  </responsible_party>
  <keyword>staphylococcus aureus</keyword>
  <keyword>nosocomial infection</keyword>
  <keyword>decolonization</keyword>
  <keyword>emergency department</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methicillin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

